SEC F	Form 4
-------	--------

FORM	4
------	---

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	tion 1(b).		d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										nours	perres	ponse.	0.5			
1. Name and Address of Reporting Person* $\underline{LaViscount\ Joyce\ N}$						2. Issuer Name and Ticker or Trading Symbol HELIUS MEDICAL TECHNOLOGIES, INC. [HSDT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (circo title				
	LIUS MED	irst) ICAL TECHNC ARDLEY ROA		3. Date of Earliest Transaction (Month/Day/Year) 10/29/2019									X Officer (give title Other (specify below) below) CFO and COO						
(Street) NEWTO (City)		A tate)		4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Ta	able I - Non	-Deriva	ative Se	ecurities Ac	quire	d, Di	isp	osed o	of, o	r Bene	ficially	Owned					
Date				2. Transa Date (Month/D		2A. Deemed Execution Date, if any (Month/Day/Yea	Cod	Transaction D Code (Instr.		4. Securi Disposed			(A) or 3, 4 and 5	) Securities Beneficia	5. Amount of Securities Beneficially Owned Following		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
							Cod	le V		Amount		(A) or (D)	Price	Transacti (Instr. 3 a	on(s)			(Instr. 4)	
						curities Acqu Is, warrants								Dwned					
1. Title of 2. 3. Transaction 3A. Deemed 4. Derivative Conversion Date Execution Date, Transaction				te, Tra	insaction							itle and A ecurities		8. Price of 9. Numb Derivative derivativ			10. Ownership	11. Nature of Indirect	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number Derivativ Securitie Acquired or Dispos of (D) (In 3, 4 and 5	e s I (A) sed str.	6. Date Exerc Expiration Da (Month/Day/N	ate	7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (Right to Buy)	\$1.73	10/29/2019 <sup>(1)(2)</sup>		A		150,000		(1)(2)	09/23/2029	Common Stock	150,000	\$0.00	150,000	D	

## Explanation of Responses:

1. Represents a stock option to purchase 150,000 shares of the Issuer's common stock (the "Option") granted pursuant to the Issuer's 2018 Omnibus Incentive Plan on September 23, 2019, which shares originally were scheduled to vest upon the achievement of a performance-based vesting milestone. Pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder, a grant of stock options subject to performance-based vesting conditions is not reportable on Form 4 until such vesting conditions are satisfied.

2. Effective October 29, 2019, the Compensation Committee of the Issuer amended the terms of the Option to replace the performance-based vesting schedule with a time-based vesting schedule, whereby 25% of the shares underlying the Option shall vest on September 30, 2020, and the remainder of the shares underlying the Option shall vest in equal monthly installments over the following 48 months, subject to the Reporting Person's continued service through each such date. Upon the establishment of the time-based vesting schedule, the award became reportable on Form 4.

## **Remarks:**

<u>/s/ Joyce LaViscount</u>

11/01/2019

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.